Dengue virus - Live attenuated (recombinant) tetravalent vaccine: only one licensed, CYD-TDV 80% efficacy preventing symptomatic virologically confirmed infection, hospitalization, and severe infection among children age 9-16 years with prior dengue infection [43] Age 9-16 years, seropositive living in endemic areas only, 3-dose series (at 0, 6, and 12 months) Japanese encephalitis virus Four main types of vaccine:
 - Inactivated Vero cell-derived vaccines (JE-VC)
 - Live attenuated vaccines (CD-JEV)
 - Live recombinant (chimeric) vaccines (JE-CV)
 - Inactivated mouse brain-derived vaccines (MB) 99% of children and 98% of adults were seroprotected at 1 month after two doses of JE-VC [44]

96% 5-year efficacy after a single dose of CD-JEV [45]

94% and 99% seroprotection at 14 days and 1 month, respectively, after one dose of JE-CV [45]

JE-VC: travel-related to endemic areas and those at increased risk, 2-dose series completed ≥ 1 week prior to travel Rabies virus For pre- (PrEP) or post-exposure prophylaxis (PEP):
 - Inactivated cell culture vaccines (e.g. human diploid cell culture, rabies vaccine adsorbed, purified chick embryo cell, purified Vero cell rabies vaccine)
 - Inactivated embryonated egg-based vaccine (e.g. purified duck embryo vaccine)
 - Inactivated nerve tissue vaccineb 92% of those who received PrEP vaccination developed an immune response [46]

PEP is 100% effective in preventing rabies when given promptly following severe exposures; PEP includes thorough wound washing, a series of timely administered rabies vaccine, and rabies immunoglobulins (RIG) if indicated [37]

Human diploid cell vaccine (HDCV) or purified chick embryo cell vaccine (PCECV): high risk for exposures as 2-dose PrEP series (on days 0 and 7); for PEP, 4-dose series (on days 0, 3, 7, and 14) for non-immunized (5th dose on day 28 for those who are immunocompromised) and 2-dose series (on days 0 and 3) for previously immunized Influenza virus - Seasonal vaccines (egg-, cell- or recombinant-based):
 - Inactivated vaccine: trivalent, quadrivalent
 - Live attenuated vaccine: trivalent, quadrivalent 19-60% effectiveness of seasonal vaccines at preventing outpatient and emergency visits, hospitalizations, and severe infection from 2009-2021 flu seasons [27] Routine annual vaccination 1 or 2 doses, age- and health status-appropriate Tick-borne encephalitis (TBE) virus Five approved inactivated vaccines:
 - Two inactivated cell culture-derived vaccines in Europe: FSME-IMMUN/TicoVac, Encepur
 - Two inactivated vaccines in Russia: TBE-Moscow, EnceVir
 - One inactivated vaccine in China: SenTaiBao 96-99% effectiveness after at least three doses of FSME-IMMUN/TicoVac [28]

62–89% protective effectiveness with the TBE-Moscow vaccine [29]

TicoVac: travel-related to endemic areas and for laboratory workers, 3-dose series, age ≥ 1 year Varicella-zoster virus - Live attenuated vaccine: monovalent, combined multiantigen vaccine (MMRV) 82% effective at preventing varicella and almost 100% effective against severe varicella after a single dose [30] VAR or MMRV: routine 2-dose series at age 12–15 months, age 4–6 yearsc Measles virus - Live attenuated vaccine: monovalent, combined multiantigen vaccine (MR, MMR or MMRV) Effectiveness of one dose of MMR vaccine is 93% against measles, 78% against mumps, and 97% against rubella [30]

Effectiveness of two doses of MMR vaccine is 97% against measles and 88% against mumps [30]

MMR or MMRV: routine 2-dose series at age 12-15 months, age 4-6 yearsc Mumps virus - Live attenuated vaccine: monovalent, combined multiantigen vaccine (MM, MMR or MMRV) MMR or MMRV: routine 2-dose series at age 12-15 months, age 4-6 yearsc Rubella virus - Live attenuated vaccine: monovalent, combined multiantigen vaccine (MR, MMR or MMRV) MMR or MMRV: routine 2-dose series at age 12-15 months, age 4-6 yearsc Severe acute respiratory syndrome coronavirus 2 Types of coronavirus disease 2019 vaccine:
 - mRNA vaccine (e.g. Pfizer/BioNTech, Moderna)
 - Viral vector vaccine (e.g. Janssen/Johnson & Johnson, Oxford/AstraZeneca)
 - Protein subunit vaccine (e.g. Novavax)
 - Inactivated vaccine (e.g. Sinovac, Sinopharm) 94-95% efficacy at preventing infection among adults after two doses of mRNA vaccine [31, 32]

72% efficacy against symptomatic infection after two standard doses of Oxford/AstraZeneca vaccine [33]

72% efficacy after one dose of Janssen/Johnson & Johnson vaccine and an increased efficacy of 94% after two doses [33]

90% efficacy against mild, moderate, and severe infection with Novavax vaccine in two Phase 3 trials [33]

51% efficacy against symptomatic infection, 100% against severe infection, and 100% against hospitalization after two doses of Sinovac vaccine in a Phase 3 trial [33]

6 months – age 17 years: 2 or 3-dose primary series, age- and health status-appropriate

Age ≥ 18 years: 2 or 3-dose primary series, health status- appropriate

Poliovirus - Two types of vaccine:
 - Orally administered live attenuated polio vaccine (OPV): monovalent, bivalent, trivalent,d mixed OPV-IPV
 - Inactivated polio vaccine (IPV): trivalent, combined multiantigen vaccine (DTaP-HepB-IPV, DTaP-IPV/Hib, DTaP-IPV, DTaP-IPV-HibHepB) 90% effective or more against paralytic polio after two doses of IPV and 99-100% effective after three doses [30] IPV: routine 4-dose series (at ages 2, 4, 6–18 months, 4–6 years) or ≥ 4 doses can be given before 4 years old when using IPV-containing combination vaccine; a dose should be given on or after 4 years old and at least 6 months following the previous dose Monkeypox virus Two available vaccines:
 - Live non-replicating vaccine (JYNNEOS)
 - Live replicating vaccinia virus vaccine (ACAM2000) Clinical efficacy or effectiveness data for mpox are currently not available [34]

Limited data on performance of JYNNEOS vaccine in the current outbreak showed that unvaccinated people have 10 times the risk of infection compared to those who were fully vaccinated and 7 times the risk compared to those with only the first dose received [35]

JYNNEOS: 2-dose series (on days 0 and 28)